Navigation Links
Global Experts Explore Entire Spectrum of Aids Vaccine Development

More than 900 attendees from 47 countries convene in Seattle for AIDS

Vaccine 2007 Conference

SEATTLE, Aug. 20 /PRNewswire/ -- More than 900 global researchers, clinicians, and specialists convene this week for the AIDS Vaccine 2007 Conference at the Sheraton Seattle Hotel and Towers. Since the AIDS Vaccine 2000 Conference in Paris, this event has emerged as the premier forum for the exchange of scientific information relating to the difficult task of developing an effective vaccine against HIV.

"It has become clear that a preventive vaccine is essential to controlling the global AIDS epidemic," says conference chair Dr. Lawrence Corey. "The conference provides a venue for the full-scale international, interdisciplinary collaboration which is critical to the development of a global AIDS vaccine."

The week-long conference which concludes on Aug. 23 will examine the entire spectrum of issues in AIDS vaccine development and deployment: including, the global effort in preventative and therapeutic vaccines, the potential development of pediatric and adolescent vaccines, clinical trials in emerging countries, and the need for strong political and financial commitment to support the scientific development of a vaccine against AIDS.

The location of the conference in Seattle is reflective of the Pacific Northwest's international leadership in the development of an AIDS vaccine. Seattle organizations contributing to the conference include the Fred Hutchinson Cancer Research Center's HIV Vaccine Trials Network, the Seattle Biomedical Research Institute, the University of Washington and the Bill & Melinda Gates Foundation.

AIDS Vaccine 2007 is the first conference to be organized under the auspices of the Global HIV Vaccine Enterprise, ( an alliance of independent organizations around the world dedicated to accelerating the development of a preventive HIV vaccine. Additionally, at this year's conference the Enterprise will release its first comprehensive report, detailing the successes and efforts of global AIDS vaccine research over the last four years.

"By hosting the conference the Enterprise furthers its purpose to help scientists work as a global community of problem solvers in the spirit of collaboration to move the best science forward as quickly as possible," says Dr. Jose Esparza, conference co-chair and interim head of the Enterprise.

The AIDS epidemic continues to grow as a global threat with the number of people living with HIV increasing in every region of the world. According to UNAIDS, the most striking increases have occurred in East Asia, Eastern Europe, and Central Asia, where the number of people living with HIV in 2006 was over one-fifth (21%) higher than in 2004.

About the AIDS Vaccine 2007 Conference For more information about the conference or for a complete program of the day's events, please visit the AIDS Vaccine 2007 Conference website at

SOURCE The AIDS Vaccine 2007 Conference

Copyright©2007 PR Newswire.

Related biology technology :

1. World Class Life Science and Pharmaceutical Companies Leverage DoveBid s Global Reach for Asset Management and Disposition
2. The state of global biotech: An Ernst & Young perspective
3. Doyle announces new energy, global warming policies
4. Lucigen Corp. enters global licensing agreement
5. Global information firm reaches diverse markets
6. Work-life imbalance - A global problem getting worse
7. Leading global Big Pharma companies of 2005
8. Learning to swim in the global talent pool
9. Federal and global guidelines on stem cell research offer a level playing field
10. Midwest life-science company Perrigo globalizes under the radar
11. The global power of WWW
Post Your Comments:
(Date:10/13/2015)... 13, 2015  Amgen (NASDAQ: AMGN ) and ... Inc. are Amgen,s 2015 selection for Golden Ticket winners, ... LabCentral is an innovative, shared laboratory space designed as ... Cambridge, Mass. Novopyxis and Cocoon ... potential life-changing therapies. --> Cambridge, Mass. ...
(Date:10/13/2015)... ... October 13, 2015 , ... The Pistoia Alliance ... Pistoia Alliance continues to drive to increase the organization’s impact on the global ... its vision and expanding its work in supporting pre-competitive collaboration in the life ...
(Date:10/13/2015)... 2015 ARRY ), Avanex Life ... JUNO ), and Progenix Pharmaceuticals, Inc. (NASDAQ: PGNX ... Corp. (OTCQX: AVXLD), Juno Therapeutics, Inc. (NASDAQ: JUNO ... --> Cooperative research and development efforts with ... lead to advancements in the treatment of severe wounds. ...
(Date:10/13/2015)... -- TapImmune, Inc. (TPIV), a clinical-stage ... and gene-based immunotherapeutics and vaccines for the treatment of ... company at the Dawson James Small Cap Growth ... Jupiter, Florida on October 15, 2015. ... immunotherapy company specializing in the development of innovative peptide ...
Breaking Biology Technology:
(Date:10/8/2015)... LAKE CITY , 8. Oktober 2015 ... TRCK), ein global tätiges Unternehmen des Bereiches ... einem Vertrag mit der Gefängnisbehörde Virginias (Department ... dessen Rahmen elektronische Überwachungsdienste für alle Strafen ... Derek Cassell , Präsident für den ...
(Date:10/7/2015)... GOTHENBURG, Sweden , October 8, 2015 ... estimates the revenues for Fingerprint Cards (FPC) during third quarter ... communicated revenue guidance of around 860 MSEK that was communicated ... Considering a further strengthened delivery capacity and a continued ... fourth quarter 2015 is estimated to be higher than during ...
(Date:10/6/2015)... SALT LAKE CITY , Oct. 6, 2015 /PRNewswire/ ... solutions company, announced today that it has signed a ... electronic monitoring services across the full range of sentences ... Track Group,s President of the Americas. "This contract with ... Eastern region of the US and advances our position ...
Breaking Biology News(10 mins):